Definium Therapeutics, Inc. (DFTX)
38.39
+0.29
(+0.76%)
USD |
NASDAQ |
Oct 29, 13:48
Definium Therapeutics Price to Book Value : 5.615 for Oct. 29, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 5.572 |
| October 27, 2026 | 5.423 |
| October 26, 2026 | 5.219 |
| October 23, 2026 | 5.217 |
| October 22, 2026 | 5.265 |
| October 21, 2026 | 5.191 |
| October 20, 2026 | 5.132 |
| October 19, 2026 | 4.822 |
| October 16, 2026 | 4.695 |
| October 15, 2026 | 5.011 |
| October 14, 2026 | 5.008 |
| October 13, 2026 | 5.028 |
| October 12, 2026 | 5.148 |
| October 09, 2026 | 5.397 |
| October 08, 2026 | 4.999 |
| October 07, 2026 | 5.132 |
| October 06, 2026 | 5.210 |
| October 05, 2026 | 5.299 |
| October 02, 2026 | 5.470 |
| October 01, 2026 | 5.499 |
| September 30, 2026 | 5.567 |
| September 29, 2026 | 5.589 |
| September 28, 2026 | 5.618 |
| September 25, 2026 | 5.290 |
| September 24, 2026 | 5.372 |
| Date | Value |
|---|---|
| September 23, 2026 | 5.507 |
| September 22, 2026 | 5.897 |
| September 21, 2026 | 5.745 |
| September 18, 2026 | 5.676 |
| September 17, 2026 | 5.657 |
| September 16, 2026 | 5.536 |
| September 15, 2026 | 5.385 |
| September 14, 2026 | 5.887 |
| September 11, 2026 | 5.688 |
| September 10, 2026 | 5.518 |
| September 09, 2026 | 5.556 |
| September 08, 2026 | 5.592 |
| September 04, 2026 | 5.571 |
| September 03, 2026 | 5.558 |
| September 02, 2026 | 5.690 |
| September 01, 2026 | 5.631 |
| August 31, 2026 | 5.809 |
| August 28, 2026 | 5.994 |
| August 27, 2026 | 6.409 |
| August 26, 2026 | 6.402 |
| August 25, 2026 | 6.554 |
| August 24, 2026 | 6.329 |
| August 21, 2026 | 6.568 |
| August 20, 2026 | 6.640 |
| August 19, 2026 | 6.702 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Enliven Therapeutics, Inc. | 3.691 |
| Cocrystal Pharma, Inc. | 12.81 |
| CNBX Pharmaceuticals, Inc. | -- |
| Arvinas, Inc. | 0.9048 |
| Fulcrum Therapeutics, Inc. | 0.9207 |
Price to Book Value Related Metrics
| PEG Ratio | -0.0827 |
| Price | 38.39 |
| Earnings Yield | -8.96% |
| Market Cap | 5.158B |
| PEGY Ratio | -0.0827 |